Previous Close | 30.34 |
Open | 30.23 |
Bid | 11.92 x 1200 |
Ask | 47.68 x 900 |
Day's Range | 29.15 - 30.23 |
52 Week Range | 19.35 - 43.61 |
Volume | |
Avg. Volume | 367,616 |
Market Cap | 1.787B |
Beta (5Y Monthly) | 0.60 |
PE Ratio (TTM) | 80.89 |
EPS (TTM) | 0.37 |
Earnings Date | Nov 07, 2022 - Nov 11, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 49.00 |
Subscribe to Yahoo Finance Plus to view Fair Value for XNCR
Xencor (XNCR) delivered earnings and revenue surprises of -26.67% and 12.15%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
MONROVIA, Calif., August 03, 2022--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported financial results for the second quarter ended June 30, 2022 and provided a review of recent business and clinical highlights.
Caris Life Sciences®(Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize health care, and Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, announced today a multi-year strategic option and license agreement to research, develop and commercialize XmAb® bispecific antibodies directed against nove